These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28360099)

  • 1. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF
    Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
    Fofana I; Krieger SE; Grunert F; Glauben S; Xiao F; Fafi-Kremer S; Soulier E; Royer C; Thumann C; Mee CJ; McKeating JA; Dragic T; Pessaux P; Stoll-Keller F; Schuster C; Thompson J; Baumert TF
    Gastroenterology; 2010 Sep; 139(3):953-64, 964.e1-4. PubMed ID: 20685314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
    Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
    J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
    Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
    Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolate-dependent use of claudins for cell entry by hepatitis C virus.
    Haid S; Grethe C; Dill MT; Heim M; Kaderali L; Pietschmann T
    Hepatology; 2014 Jan; 59(1):24-34. PubMed ID: 23775920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.
    Xiao F; Fofana I; Thumann C; Mailly L; Alles R; Robinet E; Meyer N; Schaeffer M; Habersetzer F; Doffoël M; Leyssen P; Neyts J; Zeisel MB; Baumert TF
    Gut; 2015 Mar; 64(3):483-94. PubMed ID: 24848265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.
    Shimizu Y; Shirasago Y; Kondoh M; Suzuki T; Wakita T; Hanada K; Yagi K; Fukasawa M
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29437969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.
    Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M
    J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-hepatitis C Virus Strategy Targeting the Entry Steps].
    Fukasawa M
    Yakugaku Zasshi; 2019; 139(1):89-95. PubMed ID: 30606936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins.
    Hopcraft SE; Evans MJ
    Hepatology; 2015 Oct; 62(4):1059-69. PubMed ID: 25820616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.
    Mailly L; Xiao F; Lupberger J; Wilson GK; Aubert P; Duong FHT; Calabrese D; Leboeuf C; Fofana I; Thumann C; Bandiera S; Lütgehetmann M; Volz T; Davis C; Harris HJ; Mee CJ; Girardi E; Chane-Woon-Ming B; Ericsson M; Fletcher N; Bartenschlager R; Pessaux P; Vercauteren K; Meuleman P; Villa P; Kaderali L; Pfeffer S; Heim MH; Neunlist M; Zeisel MB; Dandri M; McKeating JA; Robinet E; Baumert TF
    Nat Biotechnol; 2015 May; 33(5):549-554. PubMed ID: 25798937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.
    Paciello R; Urbanowicz RA; Riccio G; Sasso E; McClure CP; Zambrano N; Ball JK; Cortese R; Nicosia A; De Lorenzo C
    J Gen Virol; 2016 Jan; 97(1):82-94. PubMed ID: 26519290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A human claudin-1-derived peptide inhibits hepatitis C virus entry.
    Si Y; Liu S; Liu X; Jacobs JL; Cheng M; Niu Y; Jin Q; Wang T; Yang W
    Hepatology; 2012 Aug; 56(2):507-15. PubMed ID: 22378192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
    Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
    Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
    Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
    J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus.
    Zheng A; Yuan F; Li Y; Zhu F; Hou P; Li J; Song X; Ding M; Deng H
    J Virol; 2007 Nov; 81(22):12465-71. PubMed ID: 17804490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single mutation in the E2 glycoprotein of hepatitis C virus broadens the claudin specificity for its infection.
    Shirasago Y; Fukazawa H; Nagase S; Shimizu Y; Mizukami T; Wakita T; Suzuki T; Tani H; Kondoh M; Kuroda T; Yasuda S; Sato Y; Hanada K; Fukasawa M
    Sci Rep; 2022 Nov; 12(1):20243. PubMed ID: 36424447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.
    Krieger SE; Zeisel MB; Davis C; Thumann C; Harris HJ; Schnober EK; Mee C; Soulier E; Royer C; Lambotin M; Grunert F; Dao Thi VL; Dreux M; Cosset FL; McKeating JA; Schuster C; Baumert TF
    Hepatology; 2010 Apr; 51(4):1144-57. PubMed ID: 20069648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line.
    Haid S; Windisch MP; Bartenschlager R; Pietschmann T
    J Virol; 2010 Jan; 84(2):964-75. PubMed ID: 19889758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-hepatitis C virus strategy targeting host entry factor claudin-1].
    Fukasawa M
    Uirusu; 2015; 65(2):245-254. PubMed ID: 27760923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.